Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker    Newsletter   Tax Corner NRI Centre Forums E-Mail Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Sun Phar 863.00 0.59
Axis Ban 400.30 0.40
Gail
Icici Ba 1544.00 0.02
Maruti S
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-Natco Pharma Limited
Natco Pharma Limited
Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:524816NSE:NATCOPHARMBloomberg:NTCPH@INReuters:NATP.BO
Market Lot: 1Face Value: 10ISIN Demat: INE987B01018
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
28-APR-14 Natco Pharma said Monday Breckenridge Pharmaceutical, its marketing partner in the USA, has filed an Abbreviated New Drug Application (ANDA) for Bendamustine Hydrochloride powder; IV infusion (25mg/vial and 100mg/vial). 28-APR-14 Natco Pharma, one of the few Indian companies to venture into new drug discovery research, today announced that its marketing partner in the USA, Breckenridge Pharmaceutical has filed an Abbreviated New Dru...   More..
Business Profile Future Plans
One To One
Recent news
Latest News
Natco jumps as US SC denies Teva stay in Copaxone patent fight  -IRIS 21-Apr-14
Previous

More


Brief Financials (in Rs. Mn.) 
Period ending (months)30-Jun-2014(3)31-Mar-2014 (12)31-Mar-2013 (12)
Net sales 1620.005720.405143.30
Other Income8.80157.10119.40
Total Income1628.805877.505262.70
Cost of goods sold1209.204357.504023.30
OPBDIT419.601520.001239.40
PAT364.101101.90781.30
Gross Block---
Equity capital330.70330.70313.70
EPS (Rs.)-34.4924.91
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-11.31 - 25.4313.25 - 20.28
Debt / Equity (x)---
Operating margin (% of OI)25.825.923.6
Net margin (% of OI)22.418.714.8
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Natco House
Road No 2
Banjara Hills
Hyderabad
Andhra Pradesh-500 033
PHONE
(040) 2354 7532
FAX
(040) 2354 8243
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Trade On-line | Wealth Tracker | Newsletters | Tax Corner | NRI Centre | Forums | E-mail | Chat | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer